Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

436 currently recruiting clinical trials
Region Provence-Alpes-Côte d'Azur

Phase 1 / Phase 2 Lung cancer #NCT07699328 #2025-523122-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded genetic anomalies
ALK Other KRAS BRAF HER2 KRAS G12C KRAS G12D KRAS non G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Voronoi, Inc
Phase 1 / Phase 2 Lung cancer #NCT07227298 #2025-523526-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR MET NTRK-1/2/3 ROS-1
3 recruiting sites
Pfizer
Phase 1 / Phase 2 Lung cancer #NCT04939610 #2023-508995-12-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Jazz Pharmaceuticals
Phase 1 / Phase 2 Breast cancer #NCT04939610 #2023-508995-12-01
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis
Phase 1 / Phase 2 Lung cancer #NCT04939610 #2023-508995-12-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis
Phase 1 / Phase 2 Breast cancer #NCT04939610 #2023-508995-12-01
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis
Phase 1 / Phase 2 Breast cancer #NCT04939610 #2023-508995-12-01
Cancer du sein triple négatif TNBC Monotherapie
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis
Phase 1 / Phase 2 Pancreas cancer #NCT04939610 #2023-508995-12-01
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis
Phase 1 / Phase 2 Endometrial cancer #NCT06796907 #2024-517147-31-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06796907 #2024-517147-31-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Serous low grade carcinoma (LGSOC) Endometrioid carcinoma Clear cell carcinoma Mucinous carcinoma Other epithelial ovarian cancer
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline